Loading...

Viral Hepatitis, 4th Edition

Share Icon
Description

The 4th edition of Viral Hepatitis covers comprehensively the entire complex field of infections caused by all of the different hepatitis viruses, which affect many millions of people throughout the world with considerable morbidity and mortality.

Howard Thomas and Arie Zuckerman are joined by Anna Lok from the USA and Stephen Locarnini from Australia as Editors.  They have recruited leading researchers and physicians from many countries, who have produced an authoritative account of current knowledge and research on this important infection, including new insights into immune response to HBV and HCV. 

The result is a comprehensive account on all aspects of viral hepatitis, including rapid advances in the diagnosis, management, treatment and prevention of a complex infection, which in the case of hepatitis B, C and D may lead to severe complications including chronic hepatitis, cirrhosis and hepatocellular carcinoma.

The latest edition of Viral Hepatitis offers an essential resource of current information for hepatologists, gastroenterologists, infectious diseases specialists and other clinicians, researchers, public health physicians and National and International Health Authorities.

About the Author

Arie Zuckerman is chair of the Hepatitis B Foundation UK. He was the Director of?WHO Collaborating Centre for Reference and Research on Viral Hepatitis from 1974-1989 and 1990-2006. He was also?Principal and Dean of the Royal Free and University College Medical School and Principal and Dean of the Royal Free Hospital School of Medicine.

Howard Thomas?is Vice President of British Liver Trust, 1993-present and Hepatitis B Foundation — Trustee, 2005-present. He was also President of British Association for the Study of the Liver 1996-1998.

Anna Lok is a Professor of Internal Medicine and Director of Clinical Hepatology at the University of Michigan Medical Center. Her contributions include:?hepatitis B's?role in infection, treatment of hepatitis-induced diseases, development?of?cost-effective methods for preventing recurrent hep B infection following liver transplantation, and long-term effects of interferon treatment in patients with hep C.

Stephen Locarnini's research group is composed of: molecular diagnostics, new drug targets in HBV and molecular pathogenesis. Stephen is also the Director of the World Health Organisation (WHO) Collaborating Centre for Virus Reference and Research at the VIDRL.